LB Pharmaceuticals Posts $1.71 Q2 Loss Per Share, Wider Than Expected
LBRX has more than doubled off its 52-week low of $13.36.
Summary
LB Pharmaceuticals reported a Q2 loss of $1.71 per share, wider than expected, driven by higher R&D costs of $44.1 million. The significant miss raises cash burn concerns, as the company recently raised $150 million in a private placement, but this loss rate suggests the runway may shorten faster than the Q1 10-Q's projection into Q2 2029. The pivotal Phase 3 NOVA-2 trial for schizophrenia remains on track with accelerated enrollment, but the financial miss overshadows the operational update. No revenue is expected near-term, so expense control and trial timelines are now in focus.
At the time of this announcement, LBRX was trading at $46.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $13.36 to $49.14. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.